The antifibrotic drug pirfenidone promotes pulmonary cavitation and drug resistance in a mouse model of chronic tuberculosis

Pirfenidone is a recently approved antifibrotic drug for the treatment of idiopathic pulmonary fibrosis (IPF). Because tuberculosis (TB) is characterized by granulomatous inflammation in conjunction with parenchymal destruction and replacement fibrosis, we sought to determine whether the addition of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCI Insight
Main Authors: Ahidjo, Bintou A., Maiga, Mariama C., Ihms, Elizabeth A., Maiga, Mamoudou, Ordonez, Alvaro A., Cheung, Laurene S., Beck, Sarah, Andrade, Bruno B., Jain, Sanjay, Bishai, William R.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2016
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5033951/
https://ncbi.nlm.nih.gov/pubmed/27699232
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.86017
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados